secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-10-13T23:59:59+00:00
Accession:  0001396814-22-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports preliminary Q3 2022 revenue of $167.5M, up 31% YoY; EXPAREL sales up 9%
--------------------------------------------------------------------------------

- Preliminary unaudited Q3 2022 revenue $167.5M vs $127.7M in Q3 2021.
- EXPAREL net sales $132.6M (Q3 2022) vs $121.9M (Q3 2021); average daily sales 109% of prior year.
- ZILRETTA net sales $26.5M for Q3 2022; iovera° net sales $4.5M.
- Company not providing 2022 revenue or gross margin guidance due to macro uncertainty.
- Monthly intra-quarter revenue disclosure continues; weekly EXPAREL utilization data posted on investor site.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000059/0001396814-22-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000059/pcrx-20221013.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer